MedTrace Logo

Study to Evaluate Daptomycin Given During Dialysis and After Dialysis

NCT00882557 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 16

Last updated 2018-02-06

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine whether daptomycin at a higher dose given during the last 30 minutes of a dialysis session is equal to a lower dose of daptomycin given after a dialysis session.

Conditions

  • End-stage Renal Disease
  • Renal Failure Chronic Requiring Hemodialysis

Interventions

DRUG

daptomycin

intradialytic: 9 mg/kg during the last 30 minutes of dialysis

DRUG

daptomycin

6 mg/kg administered after a hemodialysis session

Sponsors & Collaborators

  • Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

    lead INDUSTRY

Principal Investigators

  • Alistair Wheeler, MD, MFPM · Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-04-29
Primary Completion
2009-07-17
Completion
2009-07-17

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00882557 on ClinicalTrials.gov